A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas


  • Rosenberg Shai
  • Simeonova Iva
  • Bielle Franck
  • Verreault Maïté
  • Bance Bertille
  • Le Roux Isabelle
  • Daniau Mailys
  • Nadaradjane Arun
  • Gleize Vincent
  • Paris Sophie
  • Marie Yannick
  • Giry Marine
  • Polivka Marc
  • Figarella-Branger Dominique
  • Aubriot-Lorton Marie-Hélène
  • Villa Chiara
  • Vasiljevic Alexandre
  • Lechapt-Zalcman Emmanuèle
  • Kalamarides Michel
  • Sharif Ariane
  • Mokhtari Karima
  • Pagnotta Stefano Maria
  • Iavarone Antonio
  • Lasorella Anna
  • Huillard Emmanuelle
  • Sanson Marc


  • Cancer genetics
  • OncogenesProtein
  • Function predictions

document type



Chordoid glioma (ChG) is a characteristic, slow growing, and well-circumscribed diencephalic tumor, whose mutational landscape is unknown. Here we report the analysis of 16 ChG by whole-exome and RNA-sequencing. We found that 15 ChG harbor the same PRKCA$^{D463H}$ mutation. PRKCA encodes the Protein kinase C (PKC) isozyme alpha (PKC$\alpha$) and is mutated in a wide range of human cancers. However the hot spot PRKCA$^{D463H}$ mutation was not described in other tumors. PRKCA$^{D463H}$ is strongly associated with the activation of protein translation initiation (EIF2) pathway. PKC$\alpha$$^{D463H}$ mRNA levels are more abundant than wild-type PKC$\alpha$ transcripts, whilePKC$\alpha$$^{D463H}$ is less stable than the PCK$\alpha$WT protein. Compared to PCK$\alpha$WT, the PKC$\alpha$$^{D463H}$ protein is depleted from the cell membrane. The PKC$\alpha$$^{D463H}$ mutant enhances proliferation of astrocytes and tanycytes, the cells of origin of ChG. In conclusion, our study identifies the hallmark mutation for chordoid gliomas and provides mechanistic insights on ChG oncogenesis.

more information